“It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial

Adaptive pragmatic clinical trials offer an innovative approach that integrates clinical care and research. Yet, blurring the boundaries between research and clinical care raises questions about how clinicians and investigators balance their patient care and research roles and what types of knowledg...

Full description

Bibliographic Details
Main Authors: Jennifer Elyse James, Galen Joseph
Format: Article
Language:English
Published: Taylor & Francis Group 2022-07-01
Series:New Genetics and Society
Subjects:
Online Access:http://dx.doi.org/10.1080/14636778.2022.2115348
_version_ 1797681260627230720
author Jennifer Elyse James
Galen Joseph
author_facet Jennifer Elyse James
Galen Joseph
author_sort Jennifer Elyse James
collection DOAJ
description Adaptive pragmatic clinical trials offer an innovative approach that integrates clinical care and research. Yet, blurring the boundaries between research and clinical care raises questions about how clinicians and investigators balance their patient care and research roles and what types of knowledge and risk assessment are most valued. This paper presents findings from an ethnographic ELSI (Ethical, Legal, Social Implications) study of an innovative clinical trial of risk-based breast cancer screening that utilizes genomics to stratify risk and recommend a breast cancer screening schedule commensurate with the assessed risk. We argue that the trial demonstrates a fundamental tension between the promissory ideals of personalized medicine, and the reality of implementing risk-stratified care on a population scale. We examine the development of a Screening Assignment Review Board in response to this tension which allows clinician-investigators to negotiate, but never fully resolve, the inherent contradiction of “precision population screening.”
first_indexed 2024-03-11T23:41:54Z
format Article
id doaj.art-be5e0b50f2174cb6ae61e59efcba4391
institution Directory Open Access Journal
issn 1463-6778
1469-9915
language English
last_indexed 2024-03-11T23:41:54Z
publishDate 2022-07-01
publisher Taylor & Francis Group
record_format Article
series New Genetics and Society
spelling doaj.art-be5e0b50f2174cb6ae61e59efcba43912023-09-19T15:22:19ZengTaylor & Francis GroupNew Genetics and Society1463-67781469-99152022-07-0141322825310.1080/14636778.2022.21153482115348“It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trialJennifer Elyse James0Galen Joseph1University of CaliforniaUniversity of CaliforniaAdaptive pragmatic clinical trials offer an innovative approach that integrates clinical care and research. Yet, blurring the boundaries between research and clinical care raises questions about how clinicians and investigators balance their patient care and research roles and what types of knowledge and risk assessment are most valued. This paper presents findings from an ethnographic ELSI (Ethical, Legal, Social Implications) study of an innovative clinical trial of risk-based breast cancer screening that utilizes genomics to stratify risk and recommend a breast cancer screening schedule commensurate with the assessed risk. We argue that the trial demonstrates a fundamental tension between the promissory ideals of personalized medicine, and the reality of implementing risk-stratified care on a population scale. We examine the development of a Screening Assignment Review Board in response to this tension which allows clinician-investigators to negotiate, but never fully resolve, the inherent contradiction of “precision population screening.”http://dx.doi.org/10.1080/14636778.2022.2115348personalized medicinerisk-stratificationrisk-based screeningbreast cancer screeningpragmatic adaptive trial designgenomicsethnographyembedded elsi
spellingShingle Jennifer Elyse James
Galen Joseph
“It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial
New Genetics and Society
personalized medicine
risk-stratification
risk-based screening
breast cancer screening
pragmatic adaptive trial design
genomics
ethnography
embedded elsi
title “It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial
title_full “It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial
title_fullStr “It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial
title_full_unstemmed “It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial
title_short “It’s personalized, but it’s still bucket based”: the promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial
title_sort it s personalized but it s still bucket based the promise of personalized medicine vs the reality of genomic risk stratification in a breast cancer screening trial
topic personalized medicine
risk-stratification
risk-based screening
breast cancer screening
pragmatic adaptive trial design
genomics
ethnography
embedded elsi
url http://dx.doi.org/10.1080/14636778.2022.2115348
work_keys_str_mv AT jenniferelysejames itspersonalizedbutitsstillbucketbasedthepromiseofpersonalizedmedicinevstherealityofgenomicriskstratificationinabreastcancerscreeningtrial
AT galenjoseph itspersonalizedbutitsstillbucketbasedthepromiseofpersonalizedmedicinevstherealityofgenomicriskstratificationinabreastcancerscreeningtrial